Rare Sugar D-Allulose Fights Postmenopausal Obesity Through GLP-1 Stimulation in Mice | Research

The takeaway

D-allulose ameliorated sucrose-induced visceral obesity and glucose intolerance in ovariectomized mice through GLP-1-dependent mechanisms, suggesting a safe dietary intervention for postmenopausal metabolic dysfunction.

GLP-1-dependent
D-allulose's metabolic benefits were completely abolished in mice lacking GLP-1 receptors, proving the rare sugar works through the same pathway as GLP-1 drugs

What the researchers found

D-allulose: reduced visceral fat, improved insulin resistance, ameliorated glucose intolerance in OVX mice. Effects abolished in GLP-1R KO mice, confirming GLP-1-dependent mechanism. Sucrose worsened metabolism only in OVX (not sham) mice.

Why it matters

Postmenopausal women face escalating metabolic risk with limited safe interventions. A dietary sugar substitute that boosts GLP-1 could be transformative.

How the study worked

OVX and sham C57BL/6J mice fed sucrose ± oral D-allulose for 2 weeks; GLP-1R KO mice for mechanism validation; metabolic assessments including visceral fat, insulin resistance, and glucose tolerance.

What this study cannot tell us

Mouse model. Two-week treatment is short. Human D-allulose GLP-1 stimulation needs quantification. Dose translation unclear.

How to read the evidence

Mechanistic mouse study with GLP-1R KO validation. Strong mechanistic proof needing human translation.

When this study was published

Published in 2025.

The bigger picture

D-allulose bridges the gap between pharmaceutical GLP-1 drugs and dietary interventions — a food ingredient that activates the same hormonal pathway.

Questions still open

Would D-allulose meaningfully boost GLP-1 in postmenopausal women?
Could D-allulose reduce the dose of GLP-1 drugs needed?
Is the GLP-1 stimulation dose-dependent with D-allulose?

Common questions

What is D-allulose?

A rare sugar that tastes sweet but has almost no calories. This study shows it stimulates the body's GLP-1 release — the same hormone targeted by drugs like Ozempic — to prevent postmenopausal metabolic problems.

Could it replace GLP-1 drugs?

Unlikely to replace them, but D-allulose could complement GLP-1 drugs or provide a milder dietary alternative. The GLP-1 stimulation from food is much smaller than from drugs.

Read the original research

GLP-1 Release by Rare Sugar D-Allulose Ameliorates Sucrose-Induced Obesity and Glucose Intolerance in Ovariectomized Mice.

International journal of molecular sciences, 27(4)

View on PubMed ↗Publisher’s paper ↗

Citation

Iba, Kengo; Kyo, Miharu; Ishihara, Hirotaka; Nagao, Aki; Kawabe, Misaki; Ohbayashi, Kento; Yada, Toshihiko; Iwasaki, Yusaku. (2026). GLP-1 Release by Rare Sugar D-Allulose Ameliorates Sucrose-Induced Obesity and Glucose Intolerance in Ovariectomized Mice.. International journal of molecular sciences, 27(4). https://doi.org/10.3390/ijms27041651